Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1241-1260 of 3,900 trials

Cirrhosis and Ascites: Fecal Microbiota Transfer Capsules

We are testing the safety of FMT capsules for patients with cirrhosis and ascites to see if they may help reduce immune activation. This study will also look for signs of effectiveness compared to a placebo.

Cirrhosis of the Liver1-2 yearsEfficacy phase (II)Standard MedicinesCost ReimbursementGastroenterologyHepatology

Childhood Epilepsy: Perampanel Treatment Study

We are studying the effects of perampanel, given with other epilepsy medications, in children under 18. The goal is to see if it helps reduce seizures and improve overall health and development.

Childhood EpilepsyEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyPediatrics

Pulmonary Embolism: Surveillance vs. Anticoagulation

We are studying whether monitoring without blood thinners is as safe and effective as using them for low-risk patients with isolated subsegmental pulmonary embolism. This trial will also assess side effects and quality of life for participants.

Isolated Subsegmental Pulmonary Embolism3-6 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesPartially RemoteCardiologyPulmonology

Peripheral T-Cell Lymphoma: New Drug Combinations

We are studying whether combining Beleodaq or Folotyn with standard chemotherapy is more effective for newly diagnosed patients with Peripheral T-Cell Lymphoma. The goal is to see if these combinations improve treatment outcomes compared to standard therapy alone.

Peripheral T-Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Cardiac Anesthesia: Eleveld Model for Propofol and Remifentanil

We are studying how well a new model predicts drug levels of propofol and remifentanil in patients undergoing heart surgery. This research may help improve anesthesia safety and effectiveness during cardiac procedures.

Heart Disorders1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal MedicineOtolaryngology

Linvoseltamab for Relapsed or Refractory AL Amyloidosis

We are studying whether linvoseltamab is safe and effective for adults with relapsed or refractory systemic light chain amyloidosis. The trial will help us understand its impact on blood response and overall health.

Relapsed or Refractory Systemic Light Chain Amyloidosis>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyInternal Medicine

Satralizumab for Pediatric Neuromyelitis Optica Spectrum Disorder

We are studying how well satralizumab works and its safety in children aged 2-11 with AQP4 antibody positive neuromyelitis optica spectrum disorder. This research aims to improve treatment options for these young patients.

Neuromyelitis Optica Spectrum Disorder (NMOSD)6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyPediatrics

Multiple Sclerosis: CD19-targeted CAR T Cell Therapy

We are testing a new CAR T cell treatment for people with relapsing or progressive multiple sclerosis. The goal is to see if it can improve symptoms and overall health.

Relapsing Multiple SclerosisProgressive Multiple SclerosisMyasthenia GravisSafety phase (I)Internal MedicineNeurology

Pancreatic Exocrine Insufficiency: Creon® Therapy Study

We are exploring how Creon® may help improve nutrition and quality of life for patients with pancreatic exocrine insufficiency after total gastrectomy. The study also looks at weight changes and gastrointestinal symptoms.

Pancreatic Exocrine Insufficiency1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Hormonal Contraceptives: Brain Effects Study

We are comparing two types of hormonal contraceptives to see how they affect brain structure and function. We're also looking at their impact on quality of life and mental health symptoms.

Hormonal Contraception≤3 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsNeurology

Cannabidiol for Refractory Childhood Epilepsy

We are studying whether adding CBD can help children with hard-to-treat epilepsy manage their seizures better. The trial also looks at how this treatment affects the quality of life for patients and their families.

Refractory Epilepsy1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Hot Flashes After Breast Cancer: Oxybutynin vs. Venlafaxine

We are studying whether oxybutynin or venlafaxine is more effective in reducing hot flashes in women using endocrine therapy after breast cancer. We will also look at side effects and personal preferences between the two treatments.

Estrogen Receptor Positive Breast Cancer3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyOncology

Immunoglobulin A Nephropathy: Ravulizumab Study

We are testing whether ravulizumab can help preserve kidney function in adults with immunoglobulin A nephropathy. The study will also assess safety and quality of life compared to a placebo.

Immunoglobulin A Nephropathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Ulcerative Colitis: Eltrekibart Treatment Study

We are studying whether eltrekibart can help adults with moderately to severely active ulcerative colitis achieve remission. This trial compares the effects of eltrekibart to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Triple-Negative Breast Cancer: 68Ga-FAPI-46 PET/CT Imaging Study

We are investigating whether a new imaging method can predict how well early-stage high-risk triple-negative breast cancer patients respond to chemotherapy and immunotherapy. This may help tailor treatments more effectively.

Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyOtolaryngology

Severe Systemic Lupus Erythematosus: Belimumab and Rituximab Study

We are investigating whether combining belimumab with rituximab can improve treatment outcomes for people with severe systemic lupus erythematosus. This study will compare this combination to standard treatments to see if it better reduces harmful autoantibodies and improves overall health.

Systemic Lupus Erythematosus>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

ANCA-Associated Vasculitis: Rituximab with Cyclophosphamide

We are studying the effects of combining rituximab with cyclophosphamide compared to rituximab alone in patients with ANCA-associated vasculitis. This research aims to find out how these treatments help maintain remission and their impact on patient health.

ANCA Vasculitis>2 yearsMonitoring phase (IV)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementRheumatology

Multiple Myeloma: Elranatamab vs. Standard Treatments

We are studying a new treatment called elranatamab for people with relapsed refractory multiple myeloma. The goal is to see how well it works compared to current therapies and to assess its safety and impact on quality of life.

Relapsed/Refractory Multiple MyelomaConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Multiple Sclerosis: Ifenprodil Study

We are investigating whether Ifenprodil can help repair nerve damage in people with Multiple Sclerosis. This study aims to see if it may improve symptoms and overall function.

Multiple Sclerosis>2 yearsSafety phase (I)Efficacy phase (II)Neurology

Advanced Triple-Negative Breast Cancer: TONIC-3 Trial

We are studying new immunotherapy strategies for patients with advanced triple-negative breast cancer. The goal is to see if these treatments are safe and effective, and to learn more about how tumors respond to them.

Metastatic Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology